Difference between revisions of "Non-small cell lung cancer, ROS1-positive"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Just 10 days left" to "Just 9 days left") |
Warner-admin (talk | contribs) m (Text replacement - "Just 9 days left" to "Just 8 days left") |
||
| Line 1: | Line 1: | ||
{|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center" | {|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center" | ||
| | | | ||
| − | <span style="font-family:Arial; font-size:300%"> Just | + | <span style="font-family:Arial; font-size:300%"> Just 8 days left to fill out a survey on how we can make HemOnc.org better and more useful.<br> |
'''Link:''' http://j.mp/2BlBaoQ | '''Link:''' http://j.mp/2BlBaoQ | ||
</span> | </span> | ||
Revision as of 13:36, 24 January 2018
|
Just 8 days left to fill out a survey on how we can make HemOnc.org better and more useful. |
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
| Section editor | |
|---|---|
 |
Travis Osterman, DO, MS Nashville, TN Twitter: TravisOsterman |
Note: these are biomarker-specific regimens, please see the main NSCLC page for other regimens.
6 regimens on this page
8 variants on this page
|
Advanced or metastatic disease, ROS1 inhibitor-naive
Crizotinib monotherapy
| back to top |
Regimen
| Study | Evidence | Efficacy |
|---|---|---|
| Shaw et al. 2014 | Phase I, >20 pts | ORR: 72% (95% CI, 58-84) |
Chemotherapy
- Crizotinib (Xalkori) 250 mg PO BID
28-day cycles
References
- Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Nov 20;371(21):1963-71. Epub 2014 Sep 27. link to original article link to PMC article contains verified protocol PubMed